Jenkins A P, Trew D R, Crump B J, Nukajam W S, Foley J A, Menzies I S, Creamer B
Gastrointestinal Laboratory, St Thomas's Hospital, London.
Gut. 1991 Jan;32(1):66-9. doi: 10.1136/gut.32.1.66.
Urinary excretion of orally administered lactulose and 51 chromium labelled ethylenediamine tetra-acetate (51Cr-EDTA) was measured in 12 healthy adult subjects and in six patients with ileostomies to assess intestinal permeability. In normal subjects, 24 hour urinary recovery of 51Cr-EDTA was significantly greater than that of lactulose (mean (SEM) 2.27 (0.15) v 0.50 (0.08)% oral dose; p less than 0.001), but in ileostomy patients recovery of the two markers was the same. In normal subjects, therefore, the difference between the two markers may arise from bacterial break-down of lactulose but not of 51Cr-EDTA in the distal bowel, urinary excretion of lactulose representing small intestinal permeation and that of 51Cr-EDTA representing both small and large intestinal permeation. The markers were then given simultaneously to nine patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatoid arthritis and osteoarthritis. The 24 hour urinary recovery of 51Cr-EDTA in the patients was significantly greater than normal (4.64 (1.20) v 2.27 (0.15)% oral dose; p less than 0.01), but that of lactulose was not significantly affected. Moreover, the increase in 51Cr-EDTA recovery was most noticeable in the later urine collections. Both of these findings suggest that NSAIDs may increase colonic permeability.
对12名健康成人受试者和6名回肠造口术患者口服乳果糖和51铬标记的乙二胺四乙酸(51Cr-EDTA)后的尿排泄情况进行了测量,以评估肠道通透性。在正常受试者中,51Cr-EDTA的24小时尿回收率显著高于乳果糖(均值(标准误)为口服剂量的2.27(0.15)% 对0.50(0.08)%;p<0.001),但在回肠造口术患者中,两种标志物的回收率相同。因此,在正常受试者中,两种标志物之间的差异可能源于远端肠道中乳果糖而非51Cr-EDTA的细菌分解,乳果糖的尿排泄代表小肠通透性,而51Cr-EDTA的尿排泄代表小肠和大肠的通透性。然后,将这些标志物同时给予9名因类风湿性关节炎和骨关节炎而接受非甾体抗炎药(NSAIDs)治疗的患者。患者中51Cr-EDTA的24小时尿回收率显著高于正常水平(4.64(1.20)%对2.27(0.15)%口服剂量;p<0.01),但乳果糖的回收率未受到显著影响。此外,51Cr-EDTA回收率的增加在后期尿液收集时最为明显。这两个发现均表明NSAIDs可能会增加结肠通透性。